SEC Filing Summary: Wound Management Technologies, Inc. (10-K)
Business Context and Reporting Period
Company: Wound Management Technologies, Inc. (WMT)
Reporting Period: Fiscal year ended December 31, 2010
Business Overview: WMT operates primarily through its subsidiary, Wound Care Innovations, LLC (WCI), marketing the patented CellerateRX® collagen-based wound care product. The company also holds patents for resorbable orthopedic products and operates Secure eHealth, LLC, a secure healthcare data platform. Manufacturing is outsourced to Applied Nutritionals, LLC.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenues | $910,420 | $288,021 |
| Gross Profit | $372,147 | $(334,664) |
| Net Loss | $(5,135,491) | $(3,016,752) |
| Loss Per Share (Basic/Diluted) | $(0.14) | $(0.10) |
| Cash and Equivalents (End of Period) | $50,835 | $(4,363) (Overdraft) |
| Total Assets | $6,783,327 | $5,058,323 |
| Total Liabilities | $3,914,535 | $2,413,561 |
| Working Capital | $(2,629,097) | $(1,971,527) |
Note: 2009 financial statements were restated to correct errors regarding warrant modifications and royalty accruals.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 216% to $910,420, driven by the addition of a sales team and expanded distribution channels.
- Cost of Goods Sold (COGS): COGS decreased 14% to $538,273, primarily because the $400,000 advance royalty payment required in 2009 was not incurred in 2010.
- Operating Expenses: General and Administrative (G&A) expenses surged 179% to $2.93 million due to increased debt-related costs and labor costs for the new sales team.
- Non-Operating Items: A significant non-cash Loss on Debt Settlement of $1.42 million was recorded in 2010 due to issuing stock to settle debt. Interest income increased 1,130% to $157,724 following the acquisition of a $1.5 million note receivable.
- Net Loss: The net loss increased 70% to $5.14 million, largely attributed to debt settlement losses and increased operating expenses.
Outlook, Risks, and Contingencies
- Going Concern: The independent auditor has issued a "going concern" qualification. The company has a working capital deficit and substantial accumulated deficit ($22.9 million). Continued operations depend on raising additional capital, which is not guaranteed.
- Liquidity Needs: Management explicitly states the need to raise additional capital in 2011 to fund operations and expansion. Financing activities generated approximately $1.8 million in 2010.
- Key Risks:
- Single Supplier: All products are manufactured by Applied Nutritionals; supply chain disruption would halt sales.
- Reimbursement: Reliance on Medicare Part B reimbursement; policy changes could adversely affect sales.
- Debt Structure: High levels of related-party debt and convertible notes with beneficial conversion features have increased interest expense and dilution.
- IRS Liability: The company is delinquent on 2004-2005 payroll taxes, with unpaid liabilities of approximately $172,484 plus penalties and interest of $204,146. A tax lien was filed in December 2009.
- Future Products: Anticipates introducing resorbable orthopedic products in 2011.
Investor Verification Checklist
- Capital Adequacy: Verify the company's ability to secure the additional financing required to avoid ceasing operations, given the "going concern" warning.
- Debt Settlements: Review the terms of recent debt conversions and the $1.42 million loss on settlement to understand the extent of shareholder dilution.
- IRS Status: Confirm the status of negotiations regarding the $376,630 total liability (principal + penalties/interest) owed to the IRS.
- Related Party Transactions: Scrutinize the $1.82 million in notes payable to related parties and the $34,813 reimbursement for health benefits to H.E.B., LLC (managed by the CEO).
- Revenue Concentration: Note that two customers accounted for over 50% of 2010 revenues ($316,750 and $228,096 respectively).